Mint Tower Capital Management B.V. bought a new stake in shares of PAREXEL International Co. (NASDAQ:PRXL) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 24,500 shares of the medical research company’s stock, valued at approximately $2,158,000. PAREXEL International makes up approximately 0.7% of Mint Tower Capital Management B.V.’s holdings, making the stock its 12th largest holding.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in PAREXEL International by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 4,205,566 shares of the medical research company’s stock valued at $365,506,000 after buying an additional 39,302 shares in the last quarter. State Street Corp increased its position in PAREXEL International by 4.3% during the 2nd quarter. State Street Corp now owns 1,744,373 shares of the medical research company’s stock valued at $151,607,000 after buying an additional 71,255 shares in the last quarter. Alpine Associates Management Inc. acquired a new position in PAREXEL International during the 2nd quarter valued at about $113,716,000. CNH Partners LLC acquired a new position in shares of PAREXEL International in the second quarter valued at about $109,948,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of PAREXEL International by 1,008.1% in the second quarter. JPMorgan Chase & Co. now owns 982,186 shares of the medical research company’s stock valued at $85,362,000 after purchasing an additional 893,551 shares during the period. 87.45% of the stock is currently owned by institutional investors.

PAREXEL International Co. (NASDAQ:PRXL) opened at $88.08 on Wednesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.45 and a current ratio of 1.45. PAREXEL International Co. has a 1-year low of $51.16 and a 1-year high of $88.10.

PAREXEL International (NASDAQ:PRXL) last announced its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. The business had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. During the same period in the prior year, the company earned $0.94 earnings per share.

Separately, Zacks Investment Research raised PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price objective on the stock in a report on Thursday, August 31st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $80.76.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/29/mint-tower-capital-management-b-v-buys-shares-of-24500-parexel-international-co-prxl.html.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related stocks with our FREE daily email newsletter.